A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel plus sorafenib in women with node positive or high-risk breast cancer.

被引：0
|
作者：
Spigel, D. R.
Molthrop, D.
Peacock, N.
Kommor, M.
Markus, T.
Vazquez, E.
Greco, F. A.
Burris, H. A.
Hainsworth, J. D.
Yardley, D. A.
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] Tennessee Oncol PLLC, Nashville, TN USA
[3] Florida Hosp Canc Inst, Orlando, FL USA
[4] Consultants Blood Disorders & Canc, Louisville, KY USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：190S / 190S
页数：1
相关论文
共 50 条
  • [1] Phase III Multicenter Trial of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel Compared With Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel As Adjuvant Therapy for Women With High-Risk Breast Cancer
    Loesch, David
    Greco, F. Anthony
    Senzer, Neil N.
    Burris, Howard A.
    Hainsworth, John D.
    Jones, Stephen
    Vukelja, Svetislava J.
    Sandbach, John
    Holmes, Frankie
    Sedlacek, Scot
    Pippen, John
    Lindquist, Deborah
    McIntyre, Kristi
    Blum, Joanne L.
    Modiano, Manuel R.
    Boehm, Kristi A.
    Zhan, Feng
    Asmar, Lina
    Robert, Nicholas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18) : 2958 - 2965
  • [2] A randomized, multicenter phase III trial comparing doxorubicin plus cyclophosphamide followed by paclitaxel or doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for high-risk breast cancer
    Loesch, D. M.
    Greco, F.
    O'Shaughnessy, J.
    Hainsworth, J. D.
    Vukelja, S. J.
    Sandbach, J.
    Boehm, K. A.
    Ilegbodu, D.
    Asmar, L.
    Robert, N. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] A pilot study of dose intense doxorubicin and cyclophosphamide followed by infusional paclitaxel in high-risk primary breast cancer
    Zujewski, JA
    Eng-Wong, J
    O'Shaughnessy, J
    Venzon, D
    Chow, C
    Danforth, D
    Kohler, DR
    Cusack, G
    Riseberg, D
    Cowan, KH
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2003, 81 (01) : 41 - 51
  • [4] A Pilot Study of Dose Intense Doxorubicin and Cyclophosphamide Followed by Infusional Paclitaxel in High-Risk Primary Breast Cancer
    Jo Anne Zujewski
    Jennifer Eng-Wong
    Joyce O'Shaughnessy
    David Venzon
    Catherine Chow
    David Danforth
    David R. Kohler
    Georgia Cusack
    David Riseberg
    Kenneth H. Cowan
    [J]. Breast Cancer Research and Treatment, 2003, 81 : 41 - 51
  • [5] Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer
    Burnell, Margot
    Levine, Mark N.
    Chapman, Judith-Anne W.
    Bramwell, Vivien
    Gelmon, Karen
    Walley, Barbara
    Vandenberg, Ted
    Chalchal, Haji
    Albain, Kathy S.
    Perez, Edith A.
    Rugo, Hope
    Pritchard, Kathleen
    O'Brien, Patti
    Shepherd, Lois E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) : 77 - 82
  • [6] A randomized, multicenter phase III trial comparing regimens of doxorubicin plus cyclophosphamide followed by paclitaxel or doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for patients with high risk breast cancer
    Loesch, D
    Greco, FA
    O'Shaughnessy, J
    Asmar, L
    Senzer, NN
    Burris, HA
    Hainsworth, JD
    Vukelja, S
    Sandbach, J
    Holmes, F
    Sedlacek, S
    Lindquist, D
    Pippen, J
    Olivares, J
    Boehm, KA
    Zhan, F
    Robert, N
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S16 - S17
  • [7] Weekly doxorubicin and daily oral cyclophosphamide followed by nab-paclitaxel for adjuvant therapy of high-risk localized breast cancer
    Cho, E.
    Wu, Q.
    Rubinstein, L.
    Linden, H.
    Gralow, J.
    Specht, J.
    Gadi, V.
    Ellis, G.
    [J]. CANCER RESEARCH, 2017, 77
  • [8] Adjuvant docetaxel plus doxorubicin and cyclophosphamide increases survival compared with fluorouracil plus doxorubicin and cyclophosphamide in women with operable node-positive breast cancer
    Roy, V
    Perez, EA
    [J]. CANCER TREATMENT REVIEWS, 2006, 32 (01) : 55 - 58
  • [9] Feasibility of adjuvant chemotherapy with doxorubicin plus docetaxel followed by sequential capecitabine in patients with node positive breast cancer.
    Lara, R
    Mayordomo, JI
    Modolell, A
    Burillo, M
    Sanz, J
    Murillo, L
    Janariz, J
    Perez, V
    Andres, R
    Tres, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 72S - 72S
  • [10] A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer
    Yardley, Denise A.
    Burris, Howard A., III
    Farley, Cindy P.
    Barton, John H.
    Peacock, Nancy W.
    Spigel, David R.
    Greco, F. Anthony
    Hainsworth, John D.
    [J]. CLINICAL BREAST CANCER, 2008, 8 (03) : 242 - 248
12345